美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Valion Bio Inc

2.08

-0.0300-1.42%

盤後：2.240.1590+7.64%19:58 EDT

成交量：11.54萬

成交額：24.82萬

市值：184.62萬

市盈率：-0.01

高：2.26

開：2.05

低：2.05

收：2.11

52周最高：80.19

52周最低：2.05

股本：88.76萬

流通股本：88.47萬

量比：1.06

換手率：13.05%

股息：- -

股息率：- -

每股收益(TTM):-210.1984

每股收益(LYR):-192.0762

淨資產收益率：-459.52%

總資產收益率：-57.13%

市淨率：0.43

市盈率(LYR):-0.01

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

Valion Bio突發人事變動：CEO Michael K. Handley被解職，8月16日正式生效

烏克蘭衞生部依據監管等效路徑正式受理Entolimod檔案進行審評

Afrri/Niaid 設計專有PBI-BM2.5方案，評估Valion Bio（納斯達克：VBIO）的Entolimod作為首個且唯一GI-ARS療法

Valion Bio獲美國國家過敏和傳染病研究所首項FDA先例研究方案用於Entolimod™；聯邦機構將全額資助BLA啓動物體內研究計劃並共同推進FDA申報

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/VBIO"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"VBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VBIO\",,,,,undefined,":{"symbol":"VBIO","market":"US","secType":"STK","nameCN":"Valion Bio Inc","latestPrice":2.08,"timestamp":1789588800000,"preClose":2.11,"halted":0,"volume":115431,"hourTrading":{"tag":"盘后","latestPrice":2.239,"preClose":2.08,"latestTime":"19:58 EDT","volume":4595,"amount":9657.7548,"timestamp":1789603137918,"change":0.159,"changeRate":0.076442,"amplitude":0.099423},"delay":0,"changeRate":-0.014218009478672893,"floatShares":884654,"shares":887589,"eps":-210.1984,"marketStatus":"已收盤","change":-0.03,"latestTime":"09-16 16:00:00 EDT","open":2.05,"high":2.26,"low":2.05,"amount":248190.53634930003,"amplitude":0.099526,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-210.1984,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789632000000},"marketStatusCode":5,"adr":0,"listingDate":1636606800000,"exchange":"NASDAQ","adjPreClose":2.11,"preHourTrading":{"tag":"盘前","latestPrice":2.07,"preClose":2.11,"latestTime":"09:28 EDT","volume":1326,"amount":2867.5269792,"timestamp":1789565284011,"change":-0.04,"changeRate":-0.018957,"amplitude":0.109005},"postHourTrading":{"tag":"盘后","latestPrice":2.239,"preClose":2.08,"latestTime":"19:58 EDT","volume":4595,"amount":9657.7548,"timestamp":1789603137918,"change":0.159,"changeRate":0.076442,"amplitude":0.099423},"volumeRatio":1.060738},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VBIO\",,,,,undefined,":{"symbol":"VBIO","floatShares":884654,"roa":"-57.13%","roe":"-459.52%","lyrEps":-192.076175,"volumeRatio":1.060738,"shares":887589,"dividePrice":0,"high":2.26,"amplitude":0.099526,"preClose":2.11,"low":2.05,"week52Low":2.05,"pbRate":"0.43","psRate":"-21.47","week52High":80.1925,"institutionHeld":0,"latestPrice":2.08,"eps":-210.1984,"divideRate":0,"volume":115431,"delay":0,"ttmEps":-210.1984,"open":2.05,"prevYearClose":36.25,"prevWeekClose":2.26,"prevMonthClose":3.57,"prevQuarterClose":12.9975,"fiveDayClose":2.4,"twentyDayClose":4.015,"sixtyDayClose":12.8475},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VBIO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-31","symbol":"VBIO","defaultRemindTime":1788183000000,"type":"split","dateTimestamp":1788148800000,"forFactor":25,"toFactor":1,"ratio":25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VBIO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VBIO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/VBIO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"VBIO","date":"2026-09-15","current":-0.009895,"percent":0.752688,"low":-0.392475,"twenty":-0.196698,"median":-0.129503,"eighty":-0.07322,"high":-0.027033,"avg":-0.150011,"sd":0.085507,"marketCap":1863936},"quantilePoints":[{"date":"2026-04-30","current":-0.311197,"twenty":-0.324163,"median":-0.319301,"eighty":-0.314439,"marketCap":2762808},{"date":"2026-05-08","current":-0.33713,"twenty":-0.336482,"median":-0.327405,"eighty":-0.314439,"marketCap":2993043},{"date":"2026-05-15","current":-0.329149,"twenty":-0.341701,"median":-0.33551,"eighty":-0.327405,"marketCap":2922183},{"date":"2026-05-22","current":-0.203146,"twenty":-0.339301,"median":-0.327405,"eighty":-0.203206,"marketCap":2758322},{"date":"2026-05-29","current":-0.18116,"twenty":-0.338751,"median":-0.311197,"eighty":-0.201597,"marketCap":2459794},{"date":"2026-06-05","current":-0.173392,"twenty":-0.33713,"median":-0.203331,"eighty":-0.18116,"marketCap":2354321},{"date":"2026-06-12","current":-0.138668,"twenty":-0.333889,"median":-0.20236,"eighty":-0.175704,"marketCap":1882829},{"date":"2026-06-18","current":-0.131547,"twenty":-0.330097,"median":-0.198754,"eighty":-0.158647,"marketCap":1786145},{"date":"2026-06-26","current":-0.136114,"twenty":-0.327754,"median":-0.18598,"eighty":-0.135201,"marketCap":1848155},{"date":"2026-07-02","current":-0.122229,"twenty":-0.327405,"median":-0.179125,"eighty":-0.130362,"marketCap":1659627},{"date":"2026-07-10","current":-0.117868,"twenty":-0.31768,"median":-0.175704,"eighty":-0.126637,"marketCap":1600412},{"date":"2026-07-17","current":-0.115133,"twenty":-0.303417,"median":-0.165705,"eighty":-0.121795,"marketCap":1563282},{"date":"2026-07-24","current":-0.06742,"twenty":-0.241361,"median":-0.149117,"eighty":-0.119839,"marketCap":915435},{"date":"2026-07-31","current":-0.065535,"twenty":-0.203355,"median":-0.136114,"eighty":-0.117713,"marketCap":889829},{"date":"2026-08-07","current":-0.064804,"twenty":-0.203188,"median":-0.130843,"eighty":-0.108033,"marketCap":879906},{"date":"2026-08-14","current":-0.040264,"twenty":-0.202832,"median":-0.129351,"eighty":-0.073786,"marketCap":546700},{"date":"2026-08-21","current":-0.027033,"twenty":-0.202055,"median":-0.126472,"eighty":-0.068316,"marketCap":506868},{"date":"2026-08-28","current":-0.145091,"twenty":-0.20046,"median":-0.129351,"eighty":-0.070603,"marketCap":2720462},{"date":"2026-09-04","current":-0.132547,"twenty":-0.198079,"median":-0.130843,"eighty":-0.073078,"marketCap":2485249},{"date":"2026-09-11","current":-0.104144,"twenty":-0.196943,"median":-0.130244,"eighty":-0.073125,"marketCap":1952695},{"date":"2026-09-15","current":-0.09941,"twenty":-0.196698,"median":-0.129503,"eighty":-0.07322,"marketCap":1863936}],"updateTime":1789612327167},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VBIO\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1135704668","title":"Valion Bio突發人事變動：CEO Michael K. Handley被解職，8月16日正式生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1135704668","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135704668?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 18:13","pubTimestamp":1786961590,"startTime":"0","endTime":"0","summary":"据美国证券交易委员会最新披露的文件显示，Valion Bio公司首席执行官Michael K. Handley已被终止职务，该决定将于今年8月16日正式生效。作为一家生物科技企业，Valion Bio在业内一直备受关注，而此番高层变动无疑为公司的未来走向增添了新的不确定性。不过，截至目前，公司方面尚未就此次人事变动的具体原因作出进一步说明。Valion Bio接下来如何平稳过渡、谁将接任这一关键职位，都将成为市场关注的焦点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VBIO","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108799602","title":"烏克蘭衞生部依據監管等效路徑正式受理Entolimod檔案進行審評","url":"https://stock-news.laohu8.com/highlight/detail?id=1108799602","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108799602?lang=zh_tw&edition=fundamental","pubTime":"2026-07-22 19:46","pubTimestamp":1784720777,"startTime":"0","endTime":"0","summary":"乌克兰卫生部已正式接受Entolimod（一种用于治疗急性辐射综合征的候选药物）的注册档案，并依据其监管等效性路径启动正式审评程序。此举标志着该药物在乌克兰的监管审批进程迈出了关键一步。\nEntolimod由Valion Bio Inc开发，此次档案受理意味着该药物在乌克兰的上市申请已进入实质性审查阶段。监管等效性路径允许乌克兰主管部门参考其他严格监管机构（如美国FDA或欧洲EMA）的审评数据与决策，以加速本国审批流程。\n这一进展为Entolimod未来在乌克兰市场的潜在获批奠定了基础，也为Valion Bio Inc拓展其全球布局提供了新的监管机遇。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VBIO","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161118562","title":"Afrri/Niaid 設計專有PBI-BM2.5方案，評估Valion Bio（納斯達克：VBIO）的Entolimod作為首個且唯一GI-ARS療法","url":"https://stock-news.laohu8.com/highlight/detail?id=1161118562","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161118562?lang=zh_tw&edition=fundamental","pubTime":"2026-06-25 19:46","pubTimestamp":1782387982,"startTime":"0","endTime":"0","summary":"美国陆军放射生物学研究所与国立过敏和传染病研究所联合设计了一项专有的PBI-BM2.5研究方案，旨在评估Valion Bio Inc（纳斯达克股票代码：VBIO）旗下药物Entolimod，将其作为首个也是目前唯一用于治疗胃肠道急性辐射综合征的候选疗法。这项专门设计的方案旨在验证该药物的有效性与安全性，标志着针对这一严重辐射损伤的治疗开发迈出了关键一步。若最终评估结果积极，Entolimod有望填补该治疗领域长期存在的空白，为受辐射影响的胃肠道系统提供首个靶向治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VBIO","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120053939","title":"Valion Bio獲美國國家過敏和傳染病研究所首項FDA先例研究方案 用於Entolimod™；聯邦機構將全額資助BLA啓動物體內研究計劃並共同推進FDA申報","url":"https://stock-news.laohu8.com/highlight/detail?id=1120053939","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120053939?lang=zh_tw&edition=fundamental","pubTime":"2026-05-05 20:01","pubTimestamp":1777982492,"startTime":"0","endTime":"0","summary":"Valion Bio公司宣布，已从美国国家过敏和传染病研究所获得针对Entolimod™的首个FDA先例研究方案。这一重要进展标志着联邦机构将全面资助该公司开展生物制品许可申请相关的动物体内研究项目，并将协同推进FDA申报流程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VBIO"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/VBIO\",params:#limit:6,delay:false,,,undefined,":[]}}